Literature DB >> 9460999

Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia.

C M Gleeson1, J M Sloan, D T McManus, P Maxwell, K Arthur, J A McGuigan, A J Ritchie, S E Russell.   

Abstract

This study examined the association between 17p allelic loss, p53 gene mutation, p53 protein expression and DNA aneuploidy in a series of adenocarcinomas arising in the oesophagus and gastric cardia. 17p allelic loss was detected in 79% (15 of 19) of oesophageal and in 83% (29 of 35) of gastric adenocarcinomas. p53 mutations were detected in 70% (14 of 20) and 63% (26 of 41) of oesophageal and of gastric adenocarcinomas respectively. Both tumour types were associated with a predominance of base transitions at CpG dinucleotides. In five cases of oesophageal adenocarcinoma, the same mutation was detected both in tumour and in adjacent dysplastic Barrett's epithelium. Diffuse p53 protein expression was detected in 65% (13 of 20) and 59% (24 of 41) of oesophageal and of gastric tumours, respectively, and was associated with the presence of p53 missense mutation (Chi-squared, P < 0.0001). DNA aneuploidy was detected in 80% (16 of 20) of oesophageal and in 70% (28 of 40) of gastric tumours. No association was found between p53 or DNA content abnormalities and tumour stage or histological subtype. In conclusion, this study detected a similar pattern of p53 alterations in adenocarcinoma of the oesophagus and gastric cardia--molecular data consistent with the observation that these tumours demonstrate similar clinical and epidemiological features.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9460999      PMCID: PMC2151218          DOI: 10.1038/bjc.1998.44

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  53 in total

1.  The 1993-94 Généthon human genetic linkage map.

Authors:  G Gyapay; J Morissette; A Vignal; C Dib; C Fizames; P Millasseau; S Marc; G Bernardi; M Lathrop; J Weissenbach
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

2.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.

Authors:  P L Blount; P C Galipeau; C A Sanchez; K Neshat; D S Levine; J Yin; H Suzuki; J M Abraham; S J Meltzer; B J Reid
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

3.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

4.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

5.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Authors:  K Neshat; C A Sanchez; P C Galipeau; P L Blount; D S Levine; G Joslyn; B J Reid
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

6.  p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer.

Authors:  S Uchino; M Noguchi; A Ochiai; T Saito; M Kobayashi; S Hirohashi
Journal:  Int J Cancer       Date:  1993-07-09       Impact factor: 7.396

7.  A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma.

Authors:  K J Cripps; C A Purdie; P J Carder; S White; K Komine; C C Bird; A H Wyllie
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

Review 8.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

9.  Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.

Authors:  T Nakamura; H Nekarda; A H Hoelscher; E Bollschweiler; N Harbeck; K Becker; J R Siewert; N ] Harbec N [corrected to Harbeck
Journal:  Cancer       Date:  1994-04-01       Impact factor: 6.860

10.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.

Authors:  R Hamelin; J F Fléjou; F Muzeau; F Potet; P Laurent-Puig; F Fékété; G Thomas
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  29 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Chang-Ping Li; Naoko Iida; Hideaki Oda; Shigetoshi Aiso; Takatoshi Ishikawa
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 4.  Open questions in oesophageal adenocarcinogenesis.

Authors:  Carlo C Maley
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

5.  TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Authors:  Kamila Novotna; Marie Trkova; Alexandr Pazdro; Milan Smejkal; Alzbeta Soukupova; Daniela Kodetova; Premysl Smejkal; Zdenek Sedlacek
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

6.  p53 abnormalities in adenocarcinoma of the gastric cardia and antrum.

Authors:  J F Fléjou; V Gratio; F Muzeau; R Hamelin
Journal:  Mol Pathol       Date:  1999-10

7.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

8.  Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Authors:  Jonine D Figueroa; Mary Beth Terry; Marilie D Gammon; Thomas L Vaughan; Harvey A Risch; Fang-Fang Zhang; David E Kleiner; William P Bennett; Christine L Howe; Robert Dubrow; Susan T Mayne; Joseph F Fraumeni; Wong-Ho Chow
Journal:  Cancer Causes Control       Date:  2008-11-07       Impact factor: 2.506

9.  Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction.

Authors:  Franziska Pühringer-Oppermann; Michael Stahl; Gisela Keller; Mario Sarbia
Journal:  J Cancer Res Clin Oncol       Date:  2006-03-15       Impact factor: 4.553

10.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.